Steven Lichtman
Stock Analyst at Oppenheimer
(3.17)
# 1,030
Out of 4,853 analysts
66
Total ratings
44.68%
Success rate
14.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $312 → $324 | $317.16 | +2.16% | 6 | May 9, 2025 | |
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $85.74 | +22.46% | 8 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $91.92 | +46.87% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $4.30 | +179.07% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $86.93 | +26.54% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $87.00 | +8.05% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $14.90 | +336.24% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $20.66 | +180.80% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $10.60 | +3.77% | 5 | May 9, 2024 | |
| ANGO AngioDynamics | Upgrades: Outperform | $12 | $10.96 | +9.49% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $95.13 | -8.55% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $102.83 | -33.87% | 2 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.81 | +332.10% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $383.10 | -24.82% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $92.69 | +13.28% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $17.39 | +762.56% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $71.18 | +19.42% | 3 | Sep 4, 2020 |
Insulet
May 9, 2025
Maintains: Outperform
Price Target: $312 → $324
Current: $317.16
Upside: +2.16%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $85.74
Upside: +22.46%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $91.92
Upside: +46.87%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $4.30
Upside: +179.07%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $86.93
Upside: +26.54%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $87.00
Upside: +8.05%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $14.90
Upside: +336.24%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $20.66
Upside: +180.80%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $10.60
Upside: +3.77%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $10.96
Upside: +9.49%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $95.13
Upside: -8.55%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $102.83
Upside: -33.87%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.81
Upside: +332.10%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $383.10
Upside: -24.82%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $92.69
Upside: +13.28%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $17.39
Upside: +762.56%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $71.18
Upside: +19.42%